Uromodulin, the most abundant protein in normal urine, is produced by cells lining the thick ascending limb (TAL) of the loop of Henle. Uromodulin regulates the activity of the potassium channel ROMK in TAL cells. Common variants in KCNJ1, the gene encoding ROMK, are associated with urinary levels of uromodulin in population studies. Here, we investigated the functional link between ROMK and uromodulin in Kcnj1 knock-out mouse models, in primary cultures of mouse TAL (mTAL) cells, and in patients with Bartter syndrome due to KCNJ1 mutations. Both global and kidney-specific Kcnj1 knockout mice showed reduced urinary levels of uromodulin paralleled by increased levels in the kidney, compared to wild-type controls. Pharmacological inhibition and genetic deletion of ROMK in mTAL cells caused a reduction in apical uromodulin excretion, reflected by cellular accumulation. In contrast, NKCC2 inhibition showed no effect on uromodulin processing. Patients with Bartter syndrome type 2 showed reduced urinary uromodulin levels compared to age and gender matched controls. These results demonstrate that ROMK directly regulates processing and release of uromodulin by TAL cells, independently from NKCC2. They support the functional link between transport activity and uromodulin in the TAL, relevant for blood pressure control and urinary concentrating ability.
Results
Uromodulin expression and processing in Kcnj1 knock-out mice. The interplay between ROMK and uromodulin was first investigated in the constitutive, global Kcnj1 KO compared to control littermates. Only male Kcnj1 −/− mice were included in this study due to their less severe phenotype and higher survival rate 23 . Histological examination of the Kcnj1 −/− kidneys evidenced hydronephrosis and severe thinning of the medulla (Fig. 1a) . At the mRNA level ( Fig. 1b ), global ROMK deficiency was reflected by a slight downregulation of uromodulin expression (Umod: 83 ± 2% of control; P < 0.05) in Kcnj1 −/− compared to Kcnj1 +/+ kidneys, whereas other TAL genes were either significantly decreased (Slc12a1: 54 ± 3% of control; P < 0.0001) or increased (Clcnkb: 163 ± 6% of control; P < 0.0001; Cldn16: 187 ± 7% of control; P < 0.0001). Of note, ROMK deletion was reflected by a significant upregulation of genes expressed in the DCT, including Slc12a3 (292 ± 37% of control; P < 0.001) and Pvalb (349 ± 63% of control; P < 0.01) and in the connecting tubule/collecting duct (CNT/CD) segments, including Aqp2 (154 ± 13% of control; P < 0.01), Scnn1b (150 ± 7% of control; P < 0.001) and Scnn1g (170 ± 4% of control; P < 0.0001), whereas the expression of proximal tubule (PT) genes Sglt2 (59 ± 4% of control; P < 0.01) and Aqp1 (64 ± 3% of control; P < 0.05) was significantly decreased in Kcnj1 −/− mice (Fig. 1b) .
Immunoblotting analyses confirmed that NKCC2 protein levels were significantly lowered in total kidney lysates from Kcnj1 −/− mice (60 ± 5% of control; n = 5; P < 0.001), strongly contrasting with total kidney uromodulin levels, which were significantly higher (300 ± 29% of control; n = 5; P < 0.001) in Kcnj1 −/− kidneys (Fig. 1c) . To identify the cellular localization of the increased uromodulin signal, we separated membrane and cytosolic fractions obtained from the kidneys of Kcnj1 −/− and Kcnj1 +/+ mice. The purity of these fractions was assessed by probing with anti-GAPDH (membrane) and anti-flotillin-1 (cytosolic). Compared to Kcnj1 +/+ kidneys, we detected an increase in uromodulin both in the membrane (232 ± 24% of control, n = 5; P < 0.01; Fig. 1d ) and cytosolic (1389 ± 433% of control, n = 5; P = 0.003; Fig. 1e ) fractions from Kcnj1 −/− kidneys.
The modifications of uromodulin expression were further analysed using confocal microscopy on sections of Kcnj1 mouse kidneys (Fig. 1f ). Although uromodulin showed a similar localization at or close to the apical membrane of TAL cells (sub-apical vesicles) in both genotypes, the signal was more intense in the Kcnj1 −/− compared to Kcnj1 +/+ kidneys. Of note, the apical staining of NKCC2 was also stronger in Kcnj1 −/− kidneys, despite the global reduction of NKCC2 expression, suggesting an overall reduction in TAL mass.
Metabolic studies indicated that Kcnj1 −/− mice presented similar body weight, BUN and creatinine clearance levels than Kcnj1 +/+ littermates, despite polyuria with diluted urine ( Table 1 ). The plasma Na + and Clconcentrations were similar between Kcnj1 −/− and Kcnj1 +/+ mice, except for a mild decrease in plasma K + concentration in Kcnj1 −/− animals.
Immunoblotting experiments showed a ~60% reduction of urinary uromodulin levels (normalized for urinary creatinine levels to account for differences in urine concentration), in Kcnj1 −/− mice compared to control mice (41 ± 11%, n = 6; p < 0.001) ( Fig. 2a ). The decreased urinary excretion was confirmed by ELISA (51 ± 4.0 µg/ mg creat. vs 102 ± 12 µg/mg creat. in Kcnj1 +/+ , n = 10/11, P < 0.001) ( Fig. 2b ). Urinary uromodulin excreted in Kcnj1 −/− mice retained similar N-glycosylation pattern compared to wild-type as PNGase F treatment led to a ~30 kDa shift compared to untreated samples (Fig. 2c) .
These data indicate that the constitutive deletion of ROMK is reflected by an apical and cytosolic accumulation of uromodulin in the TAL cells, paralleled by a lower urine excretion of the protein.
processing and excretion of uromodulin in Kcnj1 fl/fl Pax8 Cre/+ mice. To confirm that the cellular accumulation and reduced urinary excretion of uromodulin is a direct consequence of Kcnj1 deletion, and not secondary to systemic effects of chronic/global ROMK deletion (constitutive KO), we investigated uromodulin processing in an inducible, kidney-specific Kcnj1 KO mouse model. This line uses the mouse Pax8 promoter to drive the expression of a reverse tetracycline-dependent transactivator to obtain an inducible Cre expression in all kidney tubule segments 24 . The Pax8rtTA/LC-1 mice were crossed to transgenic mice harbouring floxed Kcnj1 (Penton et al., MS under revision) allowing to delete Kcnj1 after treatment with doxycycline. Compared to Kcnj1 fl/fl Pax8 +/+ littermates, Kcnj1 fl/fl Pax8 Cre/+ mice showed a significant reduction in urinary uromodulin (75 ± 3%, n = 4, P < 0.001), and a concomitant accumulation of uromodulin in the kidney (216 ± 47%, n = 4, P < 0.01) ( Fig. 3a) where it is located at the apical pole of the TAL cells (Fig. 3b ). These data confirm the direct link between ROMK and uromodulin excretion and processing in the TAL.
ROMK inhibition in primary mouse TAL cells affects uromodulin processing.
We next used a well-established system of primary mTAL cells obtained from TAL segments isolated from mouse kidneys, in order to directly assess the effect of apical transport systems on endogenous uromodulin processing. The mTAL cells cultured on permeable filters express NKCC2 and ROMK at the apical membrane and generate a lumen-positive transepithelial potential that is abolished by apical bumetanide. Critically, the mTAL cells express endogenous uromodulin, which is processed and secreted in the apical medium similar to the situation observed in vivo 25 . Differentiated monolayers of mTAL cells were exposed to non-toxic concentrations of bumetanide (a specific inhibitor of NKCC2) and BaCl 2 (a blocker of K + channels). Exposure of the apical side of primary TAL monolayers to bumetanide (100 µM) or BaCl 2 (5 mM) resulted in a robust and sustained inhibition of V te (Suppl. Fig. S1a ). Measurement of transepithelial resistance (R te ) of mTAL monolayers after 12 h exposure to bumetanide (349 ± 11 Ω/0.33 cm 2 , n = 7, P < 0.05) and BaCl 2 (389 ± 8 Ω/0.33 cm 2 , n = 7, P < 0.001) revealed a significant increase in R te compared to 0.1% EtOH vehicle (311 ± 11 Ω/0.33 cm 2 , n = 8), indicating an effective blocking of the transport (Fig. 4a ). Uromodulin levels in the apical medium were first measured after a 12 h input in order to assess baseline uromodulin excretion rates, and then after 12 h exposure to apical BaCl 2 , bumetanide or in control conditions. Compared to baseline levels, a strong decrease of apical uromodulin excretion was observed in the presence of apical BaCl 2 (BaCl 2 : 63 ± 11% of input, n = 8, P < 0.01) but not with bumetanide (100 ± 19%, n = 8) or 0.1% EtOH vehicle (142 ± 18% of input, n = 8). In parallel, the level of cellular uromodulin was largely increased www.nature.com/scientificreports www.nature.com/scientificreports/ after BaCl 2 exposure (305 ± 37% of control, n = 8, P < 0.001), whereas it remained unchanged after exposure to bumetanide (116 ± 27% of control, n = 8, P = 0.83) ( Fig. 4b ).
Since BaCl 2 is a nonspecific K + channel blocker, we exposed mTAL cells to VU591, a selective inhibitor of ROMK that is totally effective at 30 μM in rats 26 . Apical Treatment with VU591 led to a transient decrease in V te (Suppl. Fig. S1b ) and a dosage-dependent increase in R te (0.1% DMSO vehicle: 295 ± 19 Ω/0.33 cm 2 , n = 4; 30 μM VU591: 707 ± 44 Ω/0.33 cm 2 , n = 4, P < 0.001; 60 μM VU591: 957 ± 19 Ω/0.33 cm 2 , n = 4, P < 0.001) ( Fig. 4c ). This treatment led to a dosage-dependent reduction in the 12 h input-paired excretion of uromodulin to the apical side (0.1% DMSO vehicle: 82 ± 17%, n = 4; 30 μM VU591: 72 ± 8%, n = 4, P > 0.05; 60 μM VU591: 55 ± 7%, n = 4, P < 0.05) and at the 60 μM dose, an increase of cellular uromodulin (186 ± 15%, n = 3, P < 0.01) ( Fig. 4d ). These changes occurred in absence of any significant effect on cell viability (MTT assay: 95 ± 13% of vehicle, n = 3).
Kcnj1 deletion in mTAL cells leads to reduced uromodulin excretion. We next used mTAL cells to
directly test the effect of deleting ROMK on uromodulin processing. To that end, we deleted ROMK in mTAL cells obtained from Kcnj1 fl/fl mice and transfected with an adenoviral vector expressing either Cre recombinase fused with GFP (AdenoCre) or GFP alone (Mock) 27 . As expected, transfection of mTAL cells with AdenoCre resulted in a specific >90% decrease of ROMK protein expression (10 ± 4%, n = 4, P < 0.001) ( Fig. 5a ), that was reflected by a strong decrease in transepithelial lumen-positive V te and an increase in R te (Fig. 5c ). The deletion of ROMK induced a 70% decrease in the apical excretion of uromodulin (28.5 ± 3.4% compared to mock, n = 4, P < 0.001) that was paralleled by a significant cellular accumulation as assessed by Western blotting on cell lysate (123 ± 6% compared to mock, n = 4, P < 0.05) and immunofluorescent staining on mTAL monolayers ( Fig. 5b,d) . These data confirm the cell-autonomous link between ROMK activity, transepithelial resistance/voltage and handling of uromodulin in TAL cells.
Uromodulin excretion is decreased in Bartter-type 2 patients. The translational relevance of the link between ROMK function and uromodulin excretion was tested in a cohort of patients with antenatal Bartter syndrome type 2 due to KCNJ1 mutations ( Fig. 6a ; Suppl. Table S1 ). When compared to the distribution of urinary uromodulin concentrations (as assessed by ELISA 28 and normalized to creatinine) in a GFR-matched healthy reference population (n = 82), uromodulin concentration was below the 25 th percentile of the reference population in 5/7 patients. In contrast, age and gender-matched control individuals from the same families (n = 10) Table S2 ). Western blot analysis of urine samples also showed a ~70% reduction in the level of uromodulin normalized to creatinine in Bartter 2 patients compared to the related controls (36 ± 13%, n = 4, P < 0.01) with no apparent shift in molecular weight in control and deglycosylated conditions ( Fig. 6c ).
Discussion
Despite the identification of important roles of uromodulin in physiology and disease over the last decade, the regulatory mechanisms involved in its production, processing and release into the urine remain poorly characterized. Based on evidence obtained from cellular studies, mouse models and human samples, we establish for the first time a link between the function of the K + channel ROMK and the urinary excretion of uromodulin. We show that constitutive or induced genetic deletion of ROMK or its pharmacologic blockage result in defective apical excretion of uromodulin. The levels of uromodulin in urine are also significantly decreased in patients harbouring loss-of-function mutations in KCNJ1 responsible for Bartter syndrome type 2, compared to levels observed in age-matched controls from the same family or from a reference population.
Uromodulin is an abundant protein essentially produced in the epithelial cells lining the TAL, where it is apically targeted and released in the urine following proteolytic cleavage 1 . The TAL cells play a major role in the reabsorption of NaCl and divalent cations, and in the generation of the osmotic gradient allowing to concentrate urine. The transport processes operating in the TAL are somehow linked, as evidenced by the phenotype overlap observed in the various types of Bartter syndrome 29 . In fact, early studies suggested that the levels of uromodulin excretion may be lower in at least some patients with clinically diagnosed (but not genetically proven) Bartter syndrome 30, 31 . The hypothesis of a link between uromodulin excretion and ROMK was substantiated by a meta-GWAS followed by a candidate gene approach for urinary uromodulin level in 10,884 individuals of European ancestry 15 . Among 24 candidate genes expressed and known to be involved in transport processes in the TAL, the most significant SNP associated with the urinary level of uromodulin was identified in KCNJ1 coding for ROMK 15 . Also, uromodulin levels were shown to correlate with tubular handling of electrolytes in population-based studies 21, 22 .
We provide multi-level evidence supporting a direct link between the expression and activity of ROMK and the processing and excretion of uromodulin by TAL cells. In vivo studies in constitutive and inducible Kcnj1 KO www.nature.com/scientificreports www.nature.com/scientificreports/ mouse models demonstrate that deletion of ROMK leads to a marked defect in uromodulin processing in the TAL, as indicated by intracellular accumulation and lower urine excretion. The similar effects observed in the two models indicate that the influence of ROMK on uromodulin processing is independent of any long-term effect secondary to its deletion. We substantiated the link between ROMK and uromodulin using mTAL cells, which endogenously express uromodulin 25 . Pharmacologic blockade of ROMK using non-selective BaCl 2 or selective VU591, which led to the expected increase of transepithelial resistance (R te ), was associated with a marked cellular accumulation and a decrease in the apical excretion of uromodulin. The effect was specifically due to ROMK, since NKCC2 inhibition by bumetanide did not significantly reduce uromodulin excretion.
Because uromodulin excretion was significantly reduced after pharmacological inhibition and genetic deletion of ROMK and in patients harbouring KCNJ1 mutations, we can assume that ROMK channel function and not the protein expression per se modulates uromodulin excretion. Inwardly rectifying potassium (K ir ) channels are important regulators of resting membrane potential and ROMK is critical for maintaining the lumen-positive transepithelial voltage in the TAL 32 . In some cell types, membrane potential has been shown to modulate the trafficking of membrane proteins 33 . It would be interesting to test whether such membrane potential-dependent trafficking mechanism could contribute to the observed alterations in uromodulin excretion. Due to its abundant sugar moieties, uromodulin presents as a negatively charged protein at physiological pH and is associated with lipid rafts 1 . Lipid rafts themselves are rich in gangliosides and negatively charged and have been shown to act as electric field sensors and to polarize when exposed to an electric current 34 . The physiological TAL lumen-positive voltage might thus contribute to a preferential apical raft (and uromodulin) distribution that is disrupted in ROMK deficient cells.
The Bartter type 2 patients investigated here were taking numerous medications at time of sampling, including NaCl and KCl supplements, calcium and vitamin D, and indomethacin. The potential effect of these medications (individual or in combination) on the processing and urinary levels of uromodulin has not been systematically tested. It should also be pointed that the defect in uromodulin processing might contribute to the Bartter syndrome phenotype. The expression of uromodulin modulates the activity of NKCC2 and ROMK in the TAL 7, 19 , and its deletion in mouse leads to a discrete salt-losing phenotype 35 . We recently showed that defective processing www.nature.com/scientificreports www.nature.com/scientificreports/ of uromodulin (due to hepsin mutation) is causing TAL dysfunction and salt wasting 36 . All these effects could contribute to the tubular dysfunction typically observed in patients with Bartter syndrome.
Altogether, our data demonstrate that deficient ROMK function affects the processing and urinary excretion of uromodulin, supporting the mutual dependence of critical processes taking place in the TAL.
Methods
Animal models, biochemical analyses and tissue collection. Kcnj1 −/− mice 37 and wild-type (Kcnj1 +/+ ) littermates were housed in a light-and temperature-controlled environment with ad libitum access to tap water and standard chow (Diet AO3, SAFE; 25/18 GR Mucedola Srl, Settimo Milanese, Italy). Urine samples were collected using individual metabolic cages (UNO Roestvastaal BV, Zevenaar, The Netherlands) after appropriate training. Blood was collected by venous puncture or cardiac puncture at time of sacrifice and centrifuged at 2000 g for 15 minutes at 4 °C in heparin-coated tubes (Sarstedt AG, Nürnbrecht, Germany) in order to separate plasma from cells. Creatinine, electrolytes and urea were measured on a Synchron CX5 analyser (Beckman Coulter, Fullerton, CA, USA), according to the manufacturer's instructions. Urine and plasma osmolality were measured on a multi-sample osmometer (Advanced Instruments Model 2020, Norwood, MA, USA). Urinary concentration of uromodulin in mouse urine was assessed by means of a commercial ELISA kit (ab245726, Abcam, Cambridge, UK). Following the collection of urine and plasma samples, mice were sacrificed either by decapitation or by cervical dislocation following anaesthesia with isoflurane (Minrad International Inc., Orchard Park, NY, USA) for the collection of the kidneys. One kidney was immediately homogenized for protein or RNA extraction, while the other was further processed for histological analyses. Kcnj1 fl/fl mice were generated by Ozgene (Perth, Australia) as described elsewhere (Penton et al., MS under revision) and were used to obtain kidney tissue for primary mTAL cell culture. Moreover, kidney lysates, frozen tissues and urine samples were obtained from tetracycline-inducible kidney-specific Kcnj1 KO mice that had been generated by crossing the Kcnj1 fl/fl mice with Pax8-rtTA-cre mice 24 . All of the experiments were performed in accordance with the ethical guidelines at University of Zurich (Zurich, Switzerland) and the legislation of animal care and experimentation of Canton Zurich, Switzerland. The experimental protocols were approved by the appropriate licensing committee (Kanton Zürich Gesundheitsdirektion Veterinäramt; protocol ZH049/17) at the University of Zurich.
Protein samples preparation and immunoblotting. Proteins were extracted from grinded tissue using ice-cold RIPA buffer (Sigma-Aldrich, St.-Louis, MO, USA) with the addition of protease and phosphatase inhibitors (Roche, Basel, Switzerland), followed by a brief sonication and a centrifugation for 15 min at 1000 g and 4 °C to remove debris. For the membrane-cytosolic separation, mouse kidneys were solubilized in sucrose buffer (1 mM EDTA, 20 mM Imidazole and 250 mM Sucrose, pH 7.2) and pellets enriched in large plasma membranes www.nature.com/scientificreports www.nature.com/scientificreports/ ("membrane fraction") (16,000 g, 1 h, 4 °C) and in cytoplasmic proteins and cytoplasmic vesicles ("cytosolic fraction") (200,000 g, 2 h, 4 °C) were sequentially collected. Protein concentrations in kidney/mTAL lysates were determined using the bicinchoninic acid (BCA) protein assay kit (Thermo Fischer Scientific, Waltham, MA, USA), while urine was loaded according to creatinine concentration. For semi-quantitative Western blot analysis, urine samples were denatured by boiling but not reduced. For qualitative Western blot analysis, all urine samples were denatured by boiling and reduced using DTT. When indicated, these samples were N-deglycosylated using PNGase F (P70404L, New England Biolabs, Ipswich, MA, USA) according to the manufacturer's instructions. Briefly, urine samples were prepared by adding the denaturating buffer and heating for 10 minutes at 100 °C. The final reaction was prepared by adding 10% NP-40, G7 Reaction Buffer and PNGase F (H 2 O for negative controls) to the denatured samples, which were then incubated for 1 hour at 37 °C. Kidney samples were thawed on ice, normalized for protein levels, diluted in Laemmli sample buffer (Bio-Rad Laboratories Inc., Hercules, CA, USA), separated on a 7.5-10% SDS-PAGE gel and blotted onto methanol-activated PVDF membranes. Membranes were blocked for 30 min in 5% w/v non-fat dry milk solution at room temperature, followed by overnight incubation at 4 °C with primary antibodies. Thereafter, blots were washed and incubated with peroxidase-conjugated secondary antibodies, washed again and visualized by Immun-Star ™ enhanced chemiluminescence (Bio-Rad).
Immunoblots were quantified by densitometry using ImageJ 38 .
Histological analysis and immunostaining. Kidneys were fixed overnight at 4 °C in 4% formaldehyde (Sigma-Aldrich), dehydrated and subsequently embedded in paraffin. Paraffin blocks were cut into 5 µm-thick sections, deparaffinized in xylene and re-hydrated in decreasing ethanol concentrations.
Haematoxylin and Eosin (Sigma-Aldrich) staining was performed according to standard protocols and the staining was evaluated by use of a Zeiss MIRAX MIDI slide scanner (Carl Zeiss, Oberkochen, Germany). Immunostaining was performed on paraffin sections and/or 5 μm thick cryosections obtained from Kcnj1 −/− and Kcnj1 +/+ kidneys. Sections were deparaffinized in xylene and rehydrated using decreasing ethanol concentrations. Heat mediated antigen retrieval was performed using 10 mM citrate buffer (pH 6.0) for 10 min at 98 °C in a Histos Pro Rapid Microwave Histoprocessor (Milestone Inc., Shelton, CT). The sections were blocked for 30 min in PBS containing 10% normal goat serum (CL1200, Cedarlane Laboratories, Burlington, Canada) at room temperature and incubated with the primary antibody in a humidified chamber for either 2 hours at RT or overnight at 4 °C. The sections were then incubated with secondary antibodies in PBS containing 0.5% BSA for 2 hours at RT, washed and mounted using Prolong Gold Anti-fade reagent with DAPI (P36931, Thermo Fisher Scientific).
Isolation, culture and treatment of primary mouse TAL cells. Primary cell cultures of mouse TAL
(mTAL) cells were prepared from wild-type C57/BL6 (Charles River, Suzbach, Germany) mice and Kcnj1 fl/fl mice as previously described 25 . Briefly, TALs were isolated under a light microscope on the basis of morphology characteristics and cultured on permeable filter supports (Transwell-COL, pore size 0.4 µm, Corning Costar, USA) containing a DMEM:F12-based medium for 7-10 days in a humidified chamber at 37 °C and 5% CO 2 until confluent monolayers were formed. For pharmacological inhibition, primary mTAL cultures were treated at the apical side of the filter with 100 µM bumetanide (B3023, Sigma-Aldrich) or 5 mM BaCl 2 (342920, Sigma-Aldrich) for 12 hours, and 30-60 µM VU591 (SML0077, Sigma-Aldrich) followed by 2 days of serum-free conditions. Before and after each experiment the apical medium was collected for further analysis. For expression studies, adenovirus constructs used include eGFP under control of a CMV promoter (#1060, Vector Biolabs, Malvern, PA, USA) or an individual carrying also Cre-recombinase (#1700, Vector Biolabs). The transduction protocol was performed as previously described 27 . Briefly, the cells were plated onto filters and transduction was performed 24 h after plating, when cells reached approximately 70-80% of confluence. The cells were subsequently incubated for overnight at 37 °C with culture medium containing the virus at the appropriate concentration (0.2125 × 10 9 PFU/mL). Culture medium was changed every other day, and the cells were collected for analysis after 5 days. Cultures were subjected to transepithelial resistance (R te ) measurements using an EVOM-G potentiometer (World Precision Instruments, Sarasota, FL, USA) and Endohm 6 electrodes (WPI). At the end of the experiments, cells were either lysed for RNA/protein collection or fixed for immunofluorescence staining. Thiazolyl Blue Tetrazolium Bromide (MTT) assay was performed according to manufacturer instructions. Briefly, cells were incubated with 5 mg/mL MTT (Sigma-Aldrich) for 2 hours at 37 °C. MTT formazan crystals were then solubilised with DMSO and the optical density was measured at 565 nm using an Infinite M Plex microplate reader (Tecan, Männedorf, Switzerland).
Immunofluorescence staining of mTAL cells. Confluent monolayers of primary cultured mTAL cells
were fixed for 20 min on ice with 4% (w/v) formaldehyde (Sigma-Aldrich), quenched for 10 min at room temperature (RT) and permeabilised for 15 min at 37 °C in permeabilisation solution (PS: 0.7% gelatin (#G7041-100G, Sigma-Aldrich) and 0.016% saponin (#47036-50GF, Sigma-Aldrich) in H 2 O). A primary antibody detecting uromodulin was diluted in PS and incubated for 1 h at 37 °C. After four washing steps in PS, monolayers were incubated for 30 min at 37 °C in PS with a donkey anti-sheep Alexa488 (#A-11015, Thermo Fisher Scientific) secondary antibody. Next the cells were washed 3-times in PBS containing 0.1% Triton-X (#T9284, Sigma-Aldrich), post-fixated for 15 min at RT using 4% formaldehyde in PBS containing DAPI (Life technologies, #D1306), and rinsed once with PBS. The filters were cut from the holder and mounted in Prolong Gold Anti-fade reagent (Thermo Fisher Scientific). Sections and cells were viewed using a LSM510Meta Confocal microscope (Carl Zeiss, Oberkochen, Germany), with an ×63/1.4 Plan-Apochromat oil-immersion objective; x40/NA 1.25 oil immersion objective and an x20/ NA 0.7 multi immersion objective.
RNA isolation, reverse transcription and quantitative PCR. Analysis of gene expression levels in mouse kidneys and mTAL cells were performed based on the MIQUE guidelines 39 www.nature.com/scientificreports www.nature.com/scientificreports/ total RNA from mTAL cells was performed using RNAqueous-Micro kit (Ambion, Huntingdon, UK). Total RNA was extracted from kidney using Aurum TM Total RNA Fatty and Fibrous Tissue Kit (Bio-Rad, Hercules, CA), following the protocol of the manufacturer. Contamination by genomic DNA was eliminated by DNase I treatment. Reverse transcriptase reaction with iScript TM cDNA Synthesis Kit (Bio Rad) was executed with up to 1 µg of RNA. When needed, PCR products were sizefractionated on 1.5% agarose gel and stained with EZ-VisionR One (AMRESCO, Solon, OH). The variations in mRNA levels of the target genes were established by relative RT-qPCR with a CFX96TM Real-Time PCR Detection System and the iQ ™ SYBR Green Supermix (Bio-Rad) for the detection of single PCR product accumulation. 100 nM of sense and anti-sense primers were used in a final volume of 20 µl in iQ ™ SYBR Green Supermix (Bio-Rad) to perform RT-qPCR analyses (in duplicate). Primers specific to targets were designed with Beacon Design 2.0 (Premier Biosoft International, Palo Alto, CA). PCR conditions were: 95 °C, 3 min followed by 40 cycles of 15 sec, 95 °C and 30 seconds at 60 °C. The efficiency of each set of primers was determined by dilution curves (Suppl . Table S3 ). For TAL cell expression studies, Gapdh was used as a reference gene. GeNorm version 3.4 was used to characterize the expression stability of the candidate reference genes in kidney. Normalization factor was determined using 6 housekeeping genes (18 S, 36B4, Actb, Gapdh, Hprt1, Ppia) 40 . The relative changes were determined by the formula: 2 −ΔΔct and expressed as percentage relative to wild-type.
Urinary uromodulin measurements.
Patients with established diagnosis of antenatal Bartter syndrome type 2 and age-and gender-matched relatives were recruited (Suppl. Table S1 ). The reference samples were obtained from participants of the population-based, Swiss Kidney Project on Genes in Hypertension (SKIPOGH) study, and matched for age and eGFR 41 . Recruitment procedures have been previously described 41, 42 . All patients and controls gave informed consent. The experimental protocols were approved by the Ethics Committee of the Universities of Bern, Geneva, and Lausanne (Switzerland); the University of Louvain (Brussels, Belgium); and the EURenOmics consortium (FP7, 2007-2013, grant agreement no. 305608). All experiments were performed in accordance with relevant guidelines and regulations.
Urinary uromodulin concentration was measured using a well-established ELISA based on a sheep anti-human uromodulin antibody as the capture antibody, a mouse monoclonal anti-human uromodulin detection antibody, and a goat anti-mouse IgG horseradish peroxidase-conjugated protein (#172-1011, Bio-Rad) as a secondary antibody 28 . For detection, a 250 µg/L O-Phenylenediamine dihydrochloride (OPD) substrate solution was freshly prepared in phosphate-citrate buffer (0.1 M citric acid monohydrate, 0.2 M Na 2 HPO 4 , 0.006 M H 2 O 2 , pH 5.5). Human uromodulin (Millipore, Billerica, MA, USA) was used to establish the standard curve. The ELISA assay has a sensitivity of 2.8 ng/ml and a linearity of 1.0 28 . Urinary creatinine levels were measured using Beckman Coulter Synchron ® System Creatinine Assay (Unicell DxC Synchron ® clinical System), according to manufacturer instructions. Uromodulin was indexed to creatinine to correct for variations in urine concentration.
Antibodies. The following primary antibodies were used: sheep anti-uromodulin (K90071C, Meridian Life Science Inc., Cincinnati, OH, USA; 1:500 for WB and 1:300 for IF), mouse anti-uromodulin (CL 1032 A; Cedarlane Laboratories; for ELISA), mouse anti-flotillin-1 (BD 610821, BD Biosciences, Franklin Lakes, NJ, 1:500 for WB), rabbit anti-GAPDH (2118, Cell Signaling Technology, Danvers, MA, USA; 1:500 for WB), mouse anti-β actin (A5441, Sigma-Aldrich; 1:10 000 for WB, rabbit anti-NKCC2 (AB3562P, Merck-Millipore, Burlington, MA, USA; 1:500 for WB and 1:100 for IF), rabbit anti-ROMK (Penton et al., MS under revision; 1:1000 for WB and 1:5000 for IF).
Statistical analysis.
All values are expressed as mean ± SEM. Comparisons between groups were performed using Student's t-test or one-way ANOVA in case of 3 or more groups' comparisons. In the latter case, Tukey-Kramer's post hoc analysis was also performed. P values ≤ 0.05 were considered statistically significant.
